Metabolic Research

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. Research shows it enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. Clinical studies, such as the STEP 1 trial, demonstrated an average 14.9% reduction in body weight over 68 weeks with semaglutide 2.4 mg weekly.

Black Pearl Labs provides semaglutide at research-grade purity for laboratory use only. Not for human consumption.

Tirzepatide is a dual agonist of GIP and GLP-1 receptors. This dual action improves insulin sensitivity, enhances insulin secretion, and reduces appetite. In clinical studies such as SURMOUNT-1, participants experienced body weight reductions of up to 20.9% over 72 weeks with tirzepatide 15 mg weekly.

Black Pearl Labs supplies tirzepatide in research-grade purity for scientific study only. Not for human consumption.